The prevalence of multiple sclerosis (MS) and the age of affected patients are increasing
owing to increased longevity of the general population and the availability of effective …

Despite therapeutic suppression of relapses, multiple sclerosis (MS) patients often
experience subtle deterioration, which extends beyond the definition of “progression …

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that
results in significant neurodegeneration in the majority of those affected and is a common …

Sensitive and reliable protein biomarkers are needed to predict disease trajectory and
personalize treatment strategies for multiple sclerosis (MS). Here, we use the highly …

While neurofilament light chain (NfL) measurement in serum is a well-established marker of
neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are …

In multiple sclerosis (MS), a subset of chronic active white matter lesions are identifiable on
magnetic resonance imaging by their paramagnetic rims, and increasing evidence supports …

Effective biomarkers for multiple sclerosis diagnosis, assessment of prognosis, and
treatment responses, in particular those measurable in blood, are largely lacking. We have …

Objective To determine factors (including the role of specific disease modulatory treatments
[DMTs]) associated with (1) baseline,(2) on-treatment, and (3) change (from treatment start to …

Background: In progressive multiple sclerosis (MS), glial activation is thought to be a
relevant mechanism of disability progression. Therefore, in vivo assessment of the glial cell …

Age-related neurological disorders (ANDs), including neurodegenerative diseases, are
multifactorial disorders with a risk that increases with aging. ANDs are generally …